Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
about
Idiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenasesEvolving evidence in adult idiopathic intracranial hypertension: pathophysiology and managementPharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid DehydrogenasesCurrent concepts and strategies in the diagnosis and management of idiopathic intracranial hypertension in adults.Cortisol biosynthesis in the human ocular surface innate immune response.Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits.Identification of important chemical features of 11β-hydroxysteroid dehydrogenase type1 inhibitors: application of ligand based virtual screening and density functional theoryCurrent and emerging medical therapies for glaucoma.Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.Idiopathic intracranial hypertension; research progress and emerging themes.Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.Characterisation of 11beta-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat.Intraocular pressure and its correlation with midnight plasma cortisol level in Cushing's disease and other endogenous Cushing's syndromeAssessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial.Changes in lipidomic profile of aqueous humour in Fuchs endothelial dystrophy.Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity
P2860
Q26749288-C25EB94A-B9EF-43C3-BCB4-D4C5490654F4Q26765034-FA263181-E5A3-4F2A-AA8B-1C28E662E879Q26772046-84A2B60A-960E-4479-BD64-95C532D1EFD2Q30238677-A677121A-044C-4C9B-B1DC-72F951DEA61DQ35149219-99424C5C-3581-43DD-80AC-4AF8B0B9AAA7Q35166757-7764F5F6-5E93-4FB4-A20F-6B819443FB79Q35934104-F0B49CE9-0D99-4069-9C01-BE98850345FAQ36066033-3B6F370B-BA93-498C-A3E6-3DADFB0FD118Q36266034-27EB24D5-90FD-478B-923C-7C2F5C8D41C6Q36575445-3437FF8D-2D00-4607-8719-8FBDC8F67BA8Q37655884-B937629E-E914-46AA-B0BE-34FECE2CEEF1Q38148469-FF39D475-CC8F-4631-83A0-212CC10F3D08Q38934012-E2ADC3DD-2ED4-4C6A-A38E-6C508BC8D6C7Q41380558-320C7FBF-2E32-462B-A0C5-8E54FB4EBFA0Q42367345-B3DD688C-EFF2-4207-AB5A-6756D5A3C01AQ42369171-5B205634-FB3C-415E-BD82-75F414165851Q46409576-8068FB2D-B71F-448F-92EB-EF30C83A06EBQ51463179-D2C917FE-2294-491A-842D-9BCF14FF9AD5Q58896395-00C616A8-0A58-4511-8EC3-5F5CBB10ADBF
P2860
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Inhibition of 11beta-hydroxyst ...... ents with ocular hypertension.
@en
Inhibition of 11beta-hydroxyst ...... ents with ocular hypertension.
@nl
type
label
Inhibition of 11beta-hydroxyst ...... ents with ocular hypertension.
@en
Inhibition of 11beta-hydroxyst ...... ents with ocular hypertension.
@nl
prefLabel
Inhibition of 11beta-hydroxyst ...... ents with ocular hypertension.
@en
Inhibition of 11beta-hydroxyst ...... ents with ocular hypertension.
@nl
P2093
P2860
P356
P1476
Inhibition of 11beta-hydroxyst ...... ents with ocular hypertension.
@en
P2093
P2860
P304
P356
10.1093/QJMED/HCG085
P407
P577
2003-07-01T00:00:00Z